View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Pharma Talk Radio

Pharma Talk Radio

PharmaTalkRadio is a non-profit, internet radio show organized and supported by the Conference Forum to give easy and free access to helpful information to all industry professionals and students in the life sciences. The program interviews industry insiders on the latest strategies, business models, leadership styles, technologies and innovations in clinical trials, patient centricity, drug development, drug delivery and emerging biotechs.


Patients as Partners Europe 7 Minute Overview on What to Expect?


We are delighted to bring the Patients as Partners US event to Europe on February 6-7 in London. We would like to thank our European attendees at the US conference for challenging and encouraging us to bring the conference to Europe. The goal of creating patient centricity as the ecosystem within pharma can not be achieved without patient involvement.

Patients as Partners Europe is accredited by Patients Included and addresses what matters most to patients to enable them to engage in clinical research.

Patients as Partners EU is co-produced with patients, industry, academia, government and nonprofit organizations to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum.

Each session seeks to put ideas into action and must demonstrate the what, where, when and how behind the topic. This radio blog post provides a seven minute overview on what to expect at the conference. For more information about the conference, visit, www.theconferenceforum.org.


5 Minute Overview of DPharm (Disrupting Clinical Trials) Europe: What to Expect?

The 3rd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event is led by Co-Chairs Dr Sue Collier (GSK) and Dr Jeff Kasher (Patients Can’t Wait).

 

 

 

 

This radio blogcast gives a five minute overview of the event, which presents global case studies on:

– Real World Clinical Trial Strategies and Results
– New Leadership in Driving Clinical Trial Innovation
– Strategies to Validate the Siteless Trial
– Community Outreach and Education in Clinical Trials
– New Financial Models
– Patient Involvement and Engagement
– Brexit Update and Potential Impact on R&D
– Protocol Simulation
– Adaptive Trial Model

DPharm EU takes place at the Millennium Hotel in London on February 8-9, 2017. For more information, visit www.theconferenceforum.org


Clinical Trials Collaborations & Clinical Trials as a Care Option in 7 Minutes


Get a 7 minute blogcast on the 2nd annual Clinical Trials Collaboration conference. This program takes place April 3-4 in Boston. Led by Katherine Vandebelt, Global Head of Clinical Innovation at Eli Lilly, the CTC conference is the only strategic-level event in the US entirely focused on collaborations needed for 21st century drug development.

Tufts CSDD, Ken Getz will kick off the event with “How the Clinical Collaborations Landscape Is Changing and Its Impact on R&D Operations.” The CTC conference also will feature 3 first-time keynotes:

  • Takeda on their Transformational Clinical Development and Marketed Product Partnership with PRA Health Sciences with Dr Andy Plump, Director, Chief Medical and Scientific Officer, Takeda.
  • Models for Exquisite Project Delivery with Internal and External Partners with Dr Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck
  • Big Trends Impacting Clinical Development with Dr Steve Cutler, COO and CEO Designate, ICON

In addition, the CTC conference will feature:

Clinical Research as a Care Option: This collaborative session scheduled for the entire afternoon of April 4 shows us how clinical trial professionals can bring patients closer to clinical research and can find ways to make clinical trials a care option. Dr John McConnell, CEO, Wake Forest University Medical, is confirmed to keynote this section of the conference.


Immuno-Oncology 360 Conference in 5 Minutes: What to Expect?


The 3rd annual Immuno-Oncology 360° event takes place February 1-3, 2017 in NYC.  Lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI) co-present a program that provides a  360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. In this brief radio blog post, get a five minute overview on what to expect at IO360 2017! For more information on the entire event and speaking faculty, visit  www.theconferenceforum.org


PharmaTalkRadio: DPharm Team Discuss the 2016 Highlights


Members of the DPharm team engage in an informal conversation to highlight what’s happening in innovation and the latest thinking to disrupt clinical trials at the 6th annual event. Also discussed is a brief history of how this conference dedicated to applying disruptive thinking to clinical trials came to be. This conversation is well worth listening to if you plan to attend DPharm or want to get a sense of the quality and depth this program brings to clinical trial executives.

 

DPharm takes place September 20-21, 2016 at the Fairmont Copley Plaza Hotel in Boston. Also featured on September 19 is a full day on Mobile Applications to Enhancing Clinical Trials.

DPharm Link for more information or to register.

Host:
Valerie Bowling
Executive Director, DPharm

Guests:
Meredith Sands
Executive Director, Business Development, DPharm

Elizabeth Bard
Business Development Director, DPharm


Pfizer’s Blue Sky Approach to Help Transform Clinical Research


Pfizer’s “Blue Sky” approach to transforming clinical research in Parkinson’s disease is an inspiring example of patient-centric innovation. Conference Forum’s, Valerie Bowling welcomes co-host, Ed Miseta, Clinical Leader.com in a discussion with members of Pfizer’s “Blue Sky” team. Together they discuss the vision, goals and journey in taking a new approach to advancing drug development. More specifically, the Blue Sky team talks about their partnership with IBM, (first of its kind) decisions on how to use a device in a trial, real time data collection, an 1800s house for a 21st Century research and more.

Co-Hosts:
Valerie Bowling
Executive Director, The Conference Forum

Ed Miseta
Chief Editor, Clinical Leader and Contributing Writer, Life Science Leader

Guests:
Stephen Amato, PhD
Project Manager, BlueSky, Pfizer

David Caouette, MBA
Senior Director, Strategy and Operations Lead, BlueSky and Quantitative Medicine, Pfizer 

Daniel Karlin, MD
Senior Director, Quantitative Medicine, Clinical Lead, BlueSky, Pfizer

Both Drs David Caouette and Daniel Karlin are co-presenting at the DPharm conference on September 20th, 2016 in Boston. For more information, go here: DPharm.


Communicating the Good, Bad & Ugly for CMOs and R&D Leaders in Biotech

This discussion provides helpful approaches for Chief Medical Officers (CMOs) and other R&D leadership in biotech on how to communicate effectively in times of good, bad or unexpected news. Also discussed in this program are factors to evaluate for the discontinuation of a program. Dr Mark Weinberg, Chief Medical Officer and Managing Director of Halloran Consulting Group will be joined by Dr Lee Allen, CMO, Argos Therapeutics, to discuss strategic communication strategies CMOs/R&D leadership can utilize to effectively deliver unexpected or difficult news.

More specifically:

– How do you communicate successfully?
– How does a CMO manage an unexpected realization?
– Tips on being an advocate and skeptic for your programs
– Flexibility and decision making with data
– Scenario planning
– Tips on communicating to the public
– Evaluating factors for discontinuing a program
– Rationalizing your portfolio? Who decides?

Guests:
Lee Allen, MD, PhD
CMO, Argos Therapeutics

Mark Weinberg, MD, MBA
CMO and Managing DirectorHalloran Consulting Group

Producer:
Valerie Bowling
Executive Director, PharmaTalk Radio & The Conference Forum


Clinical Trial Opportunities in Puerto Rico

What is the quality, capacity and efficiency of running clinical trials in Puerto Rico? In this discussion we speak with Dr Myrto Lee, Director, PwC’s Strategy&, UK and Dr Kosmas Kretsos, Executive Director of the Puerto Rico Consortium for Clinical Investigation to learn about key initiatives and outcomes so far to make running clinical trials more attractive in Puerto Rico. For more information about conducting clinical trials in Puerto Rico, please visit www.PRCCI.org.

 

– Why consider Puerto Rico for clinical trials?
– Status of new sites to expand clinical trial networks
– Status of a central coordinator with sites to reduce bureaucracy e.g. central IRB, central invoicing
– Patient access and costs
– Patient engagement
– Access to new technologies
– Training

Guest Host:
Dr Myrto Lee
Director, PwC’s Strategy&, UK

Guest:
Dr Kosmas Kretsos
Executive Director, PRCCI (Puerto Rico Consortium for Clinical Investigation), Puerto Rico

Producer:
Valerie Bowling
Executive Director, The Conference Forum


Alternative Model to Transform a Funding Gap in Rare Disease Clinical Research


Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised by a wealthy individual primarily, in return for being in the trial. At DPharm Europe, Pfizer’s Craig Lipset interviewed on stage Alexander to share his story. We are delighted to present the journey and latest updates on PharmaTalk Radio.

– The rstory of the formation of iCancer.org.uk and the Oncolytic Virus Fund
– An alternative way to make clinical trials more accessible
– Ethical and moral issues
– A possible disruptive and sustainable model for other neglected medicines

The next DPharm: Disruptive Innovations to Advance Clinical Trials event takes place September 20-21 in Boston. DPharm Europe is scheduled for February 8-9, 2017 in London. For more information about these events or our Immuno-Oncology events, visit, www.theconferenceforum.org.

Producer:
Valerie Bowling
Executive Director, Conference Forum & Pharma Talk Radio

Guest Host:
Craig Lipset, MBA
Head of Clinical Innovation, R&D, Pfizer

Guest:
Alexander Masters
Author, Medical Campaigner and Co-Founder, iCancer.org.uk

 


A New Economic Solution to Drive Cures to Patients


Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve the necessary ROI. Cures Within Reach, FindaCure, Numbers For Good and the National Health Service in England are working together to the create a new economic solution to this problem by piloting the first ever Rare Disease Generic Drug Repurposing Social Impact Bond (SIB). This SIB would be a “pay for success” initiative, in which investors fund the proof of concept repurposing clinical trials and the government provides a payment to the SIB for any repurposed therapies that both improve patient outcomes and reduce healthcare costs. The government success payment would allow the SIB to repay the investors, and have additional funds for the next group of repurposing clinical trials, creating a sustainable funding source for generic drug repurposing.

Producer:
Valerie BowlingExecutive Director, The Conference Forum

Guest Host:
Bruce Bloom, JDPresident & CSO, Cures Within Reach

Panelists:
James PotterInvestment Director, Numbers for Good

Flóra RaffaiExecutive Director, Findacure

Dr Rick ThompsonScientific OfficerFindacure

Helpful Websites:

findacure.org.uk

numbersforgood.com


Partnering with Patients in the Development & Lifecycle of Medicines


Pharmatalk’s Valerie Bowling welcomes Anton (Tony)  Hoos, MD, PhD, Head of Medical, Amgen Europe and Marc Boutin, JD, Chief Executive Officer, National Health Council.  We address how industry and patients can work together to incorporate the patient voice in drug development and to improve patient’s experience in clinical trials. We examine the current challenges and barriers to patient involvement, progress and next steps.

 

Host:
Valerie Bowling, Executive Producer, PharmaTalk Radio

Guests:
Anton (Tony) Hoos, MD, PhD, Head of Medical, Amgen Europe  

Marc Boutin, JDChief Executive OfficerNational Health Council

Both Dr Hoos and Mr Boutin will be speaking at the Patients as Partners conference scheduled for March 14-15, 2016 in Philadelphia. For more information, visit www.theconferenceforum.org.


Immuno-Oncology Drug Development: Challenges & Next Steps

PharmaTalk Radio’s Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD, National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what’s currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps.

 

 

More specifically they also address:

– Ipilumumab/Nivo/Pembro challenges
– What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
– Challenges with the following modalities: Checkpoints, Oncolytic Virus’, Adoptive T-Cells, Cancer Vaccines
– Blinitumumab
– The more interesting agents in late stage development now in immunotherapy and its promise
– Immune related adverse events
– Adoptive cellular therapies, what is the most promising?
– Will IO become backbone therapies for cancer?
– What’s the next set of assets that are going to come out?
– What can we expect within the next year or two?

Guests:
James Gulley, MD, PhD
Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline

The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016  at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.

 


Making Clinical Trials a Care Option for Patients

This talk demonstrates how an organized multi-specialty healthcare system, clinical research site network and pharma company uses clinical research as a tool and connector to help improve patient engagement in their overall healthcare management and compliance.
More specifically:

– Healthcare System: improving health and service to patients and advocators of clinical research participation
– Clinical Research Site Network: bringing the right patients to the right trials with increased quality of data and engagement of patients
– Pharma: expanding our reach to patients and getting trials done faster
– Shifting the paradigm: Applying a Value Based Health Care Delivery Framework to improve outcomes and reduce healthcare costs

Hosted by: Katherine Vandebelt Global Head, Clinical Innovation, Eli Lilly and Company

Guests:
Jeff James, MBA, CEO, Wilmington Health

Jennifer Byrne, CEO, PMG Research

Allen Buechler, MBA, Strategy and Operations, Eli Lilly and Company

Toyin Okanlawon, MD, MPH, Senior Health Care Researcher, Harvard Business School Health Care Team

For more information on cutting edge topics in clinical research/trials visit:

Dpharm US, visit www.theconferenceforum.org

Dpharm Europe, visit www.theconferenceforum.org

 


The Safety Elements of Immuno Cancer Therapies

In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference. Her talk focuses on immune related adverse affects of immuno therapy. More specifically, she covers:

– Identifying warning signs and low threshold for workup and treatment
– Understanding “pseudoprogression” before response, delayed toxicities
– Reporting and assessing adverse effects during clinical trial phases
– How to predict safety concerns when moving from animal models to human trials

 

We are pleased to bring this session to the public to help researchers, doctors, patients and care givers with some information on immune related adverse affects of immuno therapy. Please note that Dr Pavlick does occassionally refer to slides which are not included in the recording of this session.

Anna Pavlick, DO, MD is the Director of the NYU Cancer Institute Melanoma Research Program. After finishing her studies at University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine, Dr Pavlick completed her residency in internal medicine and her fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. In 1999, she went on to become the Director of Clinical Oncology at UMDNJ in New Jersey before coming to NYU.

The next IO360 conference will take place February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, visit www.theconferenceforum.org.

PharmaTalkRadio is a non-profit program organized and supported by the Conference Forum to give easy and free access of helpful information to all industry professionals and students in the life sciences.

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


The Journey of a Physician CEO with David Schenkein, MD, CEO, Agios

At the Conference Forum’s 2015 Chief Medical Officer’s Summit in Boston, David Schenkein, MD, CEO, Agios provided a warm and personal keynote sharing his journey as a Physican CEO. In this recording of the session, gain an insight into Dr Schenkein’s views on leadership in running a biotech company and more specifically:

– The journey
– The people and mentorships
– Prioritizing resources
– Successes and failures
– Overcoming hurdles
– Strategic partnerships
– Business planning
– Audience Q&A

This is a great session for leadership and aspiring leadership in life sciences and beyond.

The Chief Medical Officer West Summit is this November 9-10 in the San Francisco area. See www.theconferenceforum.org for speaker line up and agenda information. The CMO West conference is dedicated to addressing the unique challenges faced by CMOs and their staff in managing R&D in emerging biotechs.

PharmaTalkRadio is a non-profit program organized and supported by the Conference Forum to give easy and free access of helpful information to all industry professionals and students in the life sciences.

 


Clinical Air Episode #14: Consumer Electronics in Clinical Research

Clinical Air Episode #14 is pleased to present a discussion on Consumer Electronics in Clinical Research. Craig Lipset, Head of Clinical Innovation R&D at Pfizer welcomes guests from Rebar Interactive and Eli Lilly to address and explore an update on what’s available, what’s capable and what’s working with consumer electronics in clinical research. We explore topics including, but not limited to:

-How to scale new tools
-The level of validation of different instruments
-The impact of tools like the Apple Research Kit
-What future apps will offer

 

 

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Rahlyn Gossen, Founder, Rebar Interactive

Michael Luker, Director, Clinical Innovation, Eli Lilly

Katherine Vandebelt, Senior Director, Clinical Development Innovation, Eli Lilly

*Please note this session has some background sound interference at the start of the program.

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Immuno-Oncology: Exploring the Challenges & Potential

Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today. However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we were pleased to welcome to Pharma Talk Radio, James Gulley, MD, PhD of the National Cancer Institute and Roy Baynes, MD, PhD at Merck Research Labs. Joining Drs Gulley and Baynes is Kate Woda, Director of the IO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC.

Host:
Valerie Bowling, Producer, Pharma Talk Radio

Guests:
James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

Roy Baynes, MD, PhD, SVP, Global Clinical Development, Merck Research Labs

Kate Woda, Director, IO 360

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Design Thinking for Clinical Trials

Design Thinking is a human centered approach to innovation that helps uncover the sweet spot of opportunity where the needs of people, the possibilities of technology and the requirements for business success all converge. The application of the Design Thinking methodology (originating out of Stanford’s d.School) as a new approach to looking at solutions can lead to disruptive innovation in clinical trials for drug development. It allows for designing new ways of working, including the needs, challenges and insights about the complex world we work in.

In this discussion, we introduce the basic principals of Design Thinking and an understanding of how the methodology teaches empathy for the end user (the patients). We explore its ability to reframe questions and unleash innovative thinking as well as the “downside” of creative tension. Most importantly, we address how Design Thinking can drive more successful trials.

Host:
Valerie Bowling, Executive Director, The Conference Forum

Guests:
Kate Helber, Co-Founder, The Helber Group

Jen Reichuber, Co-Founder, The Helber Group

Komathi Stem, Strategic Innovation Leader, Genentech/Roche

Kate, Jen and Komathi will also be leading a hands-on program, May 11-12 in Boston. For more information, click here.

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #13: TransCelerate & Industry Engagement

In September 2012, TransCelerate Biopharma launched with the aim of simplifying and accelerating the delivery of innovative medicines to patients. What progress has really been made and what are the realistic goals for 2015? In our 2015 kick off radio show, Clinical Air Episode #13, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Dalvir Gill, PhD, CEO of TransCelerate and Andy Lee, MD, SVP, Head of Global Clinical Trial Operations at Merck.

 

In this frank discussion, we learn:

– What’s working well and changes for 2015?
– Is TransCelerate performing better or differently from other collaborations?
– How have engagements with outside organizations advanced? Where do gaps remain?
– How are new areas selected and scope defined?
– Thoughts on implementing new ideas
– New role for CROs
– What deliverables does TransCelerate anticipate for 2015?

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Dalvir Gill, PhD, CEO, TransCelerate

Andy Lee, MD, SVP, Head of Global Clinical Trial Operations, Merck

Producer
Valerie Bowling, Executive Director, The Conference Forum

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Risk Based Monitoring: New Thinking on Clinical Oversight

Since the FDA and EMA published their current thinking on clinical oversight and risk-based monitoring (RBM) strategies, the topic has received a magnitude of attention, commanding column inches, webinar discussions and industry conferences. With so much discussion going on, it is unsurprising that many sponsors are feeling out in the cold when it comes to identifying how to practically implement RBM strategies within study designs. As data quality matters most in determining study success and ensuring patient safety, the latest recommendations have created growing demand for solutions that simplify the transition to risk-based techniques.

In this program, our guests discuss how emerging technologies and Central Statistical Monitoring (CSM) now present more practical means of implementing successful RBM strategies. Both Sanofi and Novartis will provide a large pharma perspective on making the move to RBM.

Host:
Valerie Bowling
Executive DirectorThe Conference Forum

Guests:
Marc Buyse
FounderInternational Drug Development Institute & CluePoints

Eric Genevois-Marlin
VP, Biostatistics & ProgrammingSanofi

Thomas Haag
Data Integrity Process Expert, eClinical Quality AssuranceNovartis Pharmaceuticals

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode # 12: Digital Startups & Applications for Clinical Research

In Clinical Air Episode #12, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Marc Sluijs, Director Life Science Business Development at Oracle Health Sciences.

Marc shares his thoughts on the digital health space and where technology is heading in clinical trials. In this informal discussion, Craig and Marc also cover how digital technologies can better serve patients as well as tips on keeping tabs on this rapidly moving space and what can disrupt pharma?

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guest:
Marc Sluijs, Director Life Science Business Development, Oracle Health Sciences

Producer:
Valerie Bowling, Executive Director, The Conference Forum

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode # 11: How can Digital Complement and Disrupt Clinical Trials

Donald Jones, Chief Digital Officer, Scripps Translational Science Institute talks with host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer on what’s happening with digital in drug development. Don discusses his thoughts on the evolution of new products with digital and the “digitazation” of tools for clinical trials. He also shares his thoughts on the biggest disruptors in pharma.

Don and Craig will be featured in an interview as well at DPharm: Disruptive Innovations to Advance Clinical Trials on September 11, 2014 in Boston.

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guest:
Donald Jones, Chief Digital Officer, Scripps Translational Science Institute & Founder & Chairman, Wireless Life Sciences Alliance

Producer:
Valerie Bowling, Executive DirectorThe Conference Forum

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode # 10: Patients as Partners in Clinical Trials

Join host, Craig Lipset,  Head of Clinical Innovation, R&D, Pfizer as he leads a discussion on what it really means to partner with patients in clinical trials.

Guests include:
Jeri Burtchell, Founder, Partners in Research

Regina Holliday, Artist and Medical Advocate

For more information on Jeri’s new launch, visit Healthivibe.com and for Regina walking gallery, google Regina Holliday, walking gallery.

For more information on the topic of Patients as Partners, visit www.theconferenceforum.org. The Conference Forum presented a program in March 2014 fully dedicated to understanding the journey a patient takes in clinical trials. Also take a look at Disruptive Innovations to Advance Clinical Trials scheduled for September 11-12, 2014 in Boston. This event addresses significant innovation to help improve a patients experience in a clinical trial.

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode # 9: Investing in the Future of Clinical Research

Join host, Craig Lipset,  Head of Clinical Innovation, R&D, Pfizer as he leads a discussion on Investing in the future of clinical research.

Guests include:

Todd Pietri, Co-Founder, Milestone Ventures

Jeremy Sohn, Managing Director, MPM Capital

 

 

 

 

VC views on:

-Disruption in the clinical trial space
-Entrepreneurs
-Finding opportunities (incubators and accelerators)
-Good sources of deal flows
-Investing in technology or people?
-Mobile
-Big data
-Beyond the pill
-and more….

Craig, Todd and Jeremy will also be speaking at Mobile@DPharm on September 10 at the Fairmont Copley Plaza hotel in Boston. This event helps drug developers get their arms around the mobile/digital clinical trial landscape and figure out:

-How mobile is innovating clinical trials
-What parts of clinical trials mobile/digital technology is currently impacting
-How mobile technology is making clinical trials cheaper, easier and more accurate
-How mobile/digital is increasing the efficacy of drugs
-What the true value is to clinical trials
-Opportunities

There is an opportunity to participate in creating a clinical trial app. Mobile@DPharm will also be of interest to investors and app developers. Following this one day event is DPharm: Disruptive Innovations to Advance Clinical Trials. For more information, visit www.theconferenceforum.org or call 646 350 2580.

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode # 8: Investigators as Partners in Clinical Research

In Clinical Air episode #8, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer hosts a show discussing investigators as partners in clinical research. Guests include:

Christine Pierre, President, Society of Clinical Research

Jacalyn Kent, Director, Clinical Development Information & Optimization, Eli Lilly

 

 

 

 

Key topics include:

-Misunderstandings around Remote Based Monitoring
-Training and communication challenges for remote site managers
-Transcelerate update
-What are the real cost savings around RBM…are we just shifting costs?
-Real time data and how this should affect sites and payments
-Reducing burdens to the sites
-Investigator turn over rate, making sites sustainable

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode # 7: Engaging Patients by Sharing Electronic Clinical Data

In 2013 Pfizer launched the Pfizer Blue Button Project, a first-of-it’s-kind initiative enabling patients who have participated in clinical trials the opportunity to download their individual clinical data. Using the Blue Button standard launched by the White House, patients will be empowered to use the data to improve their overall health and wellness, from sharing with healthcare providers to powering clinical risk assessments. In this show, our host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer speaks to the leaders behind these initiatives to find out why they launched, initial learnings, and where the projects may go if successful. Also joining Craig is Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team.

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Adam Dole, Presidential Innovation Fellow, The White House

Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team

Jennifer Wulff, Director, Clinical Innovation, Pfizer

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Barriers and Limitations in Engaging Patients in Clinical Trials

Join guests Kerri Weingard, ANP, COO, Verified Clinical Trials and Susan Salgado, PhD, Founder, Hospitality Quotient as they identify the barriers and limitations in engaging patients in clinical trials. What we can do about it through communication and service? Hosted by Valerie Bowling, Executive Director, the Conference Forum, this episode addresses one of the hottest topics at the Patients as Partners event scheduled for March 3-4, 2014 in Philadelphia. For more information, visit www.theconferenceforum.org.

About Our Guests:
Susan Reilly Salgado, PhD founded Hospitality Quotient with Danny Meyer in 2010. Hospitality Quotient offers customized advice and training to inspire, build and sustain a company culture of service in organizations across industries. In addition to her PhD, Susan holds a BS and an MBA from Lehigh University. Susan has also served as an instructor in organizational behavior and business strategy at NYU and as a guest lecturer at Lehigh.

Kerri Weingard is the chief operating officer at Verified Clinical Trials (VCT), a New York-based firm specializing in ensuring the integrity of medical studies and clinical trials by creating a database of research study participants trials. Ms. Weingard, who is a nurse practitioner, holds a master’s degree in science from Stony Brook University. She has conducted over 500 clinical trials as a research coordinator and sub-investigator.

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #6: Clinical Trial Visits of the Future

How a patient experiences a clinical trial is changing. Access, ease, efficiencey, safety and better quality data collection are the target goals. This episode features some of the emerging technologies together with a discussion on the opportunities and challenges to include patient access, recruitment and retention. Predictions for 2014 are shared by our guests.

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Tomasz Sablinski, MD, PhD, Founder & CEO, Transparency Life Sciences

Komathi Stem, Senior Director, Product Development, Innovation Lead, Genentech, A Member of the Roche Group, United States

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #5: Applications for Mobile/Sensors in Clinical Research

This episode provides a recap on what’s happening with mobile/sensors in clinical trials especially as they affect patients.

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Tim Davis, CEO & Co-Founder, Exco InTouch

Abbe Steel, Vice President of Patient & Physician Services, UBC

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #4: Clinical Innovation Continuum

Eli Lilly and Quintiles entered into a co-investment partnership to develop a new solution using computer-assisted designs that emphasize the improvement of scientific and operational outcomes of clinical trials. The results were shared at the DPharm 2013 event and project leaders from both companies will talk to our host Craig Lipset on how this formation is doing a year later. Also joining Craig is Jeff Lee, CEO, Omniscience to discuss featured news and trends in clinical trial innovation and in particular mobile applications.

 

 

 

 

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Jeffrey Kasher, PhD, VP & COO, Eli Lilly & Company

Jeff Lee, CEO, Omniscience Mobile

Rick Sax, MD, SVP Clinical Design & Reporting Services, Quintiles

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #3: DPharm & Beyond

A panel of executives from leading pharma and the venture capital community at the DPharm Disruptive Innovations conference recently awarded the 2013 Disruptive Innovator of the Year title to Medidata Solutions and Spaulding Clinical Research. They won for their collaboration on a novel study evaluating the impact of mobile and cloud-based technology on patient engagement for improved health outcomes in the diabetes community.

Host Craig Lipset, Head of Clinical Innovation, R&D at Pfizer speaks with Andrew Lee, MD, of Sanofi on key takeaways from the 2013 DPharm conference along with the CEOs of the winning companies to learn more about their collaboration.

 

Guests:
Andrew Lee, MD, SVP, Deputy Head of Clinical Sciences & Operations, Sanofi

Glen De Vries, President, Medidata Solutions

Randy Spaulding, Founder & CEO, Spaulding Clinical Research

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #2: To Serve Patients in Clinical Trials

-Join us in a discussion on serving patients in clinical trials.
-Making clinical trials more accessible for patients
-Emerging technologies / iPads and informed consent
-Disruption
-Headlines in the news

Host:
Craig Lipset, Head of Clinical Innovation, R&D, Pfizer

Guests:
Andreas Koester, MD, PhD, VP, Clinical Innovation & External Alliances, Janssen

Anthony Costello, CEO, Mytrus

 

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Managing the Role of Chief Medical Officer in a Biotech

The CMO of a biotech is like no other job in the world. The CMO is not only responsible for delivering on clinical trials, but also is a key player in the company’s fundraising efforts.

From the Chief Medical Officer Summit, please join co-chairs Drs. Greg Fiore, CMO of the The Medicines Company and Steven Zelenkofske, CMO, Regado together with opening presenter Dr. Tyler Martin, CMO & Founder of Great Plains Biotechnology, to discuss the role of the CMO and how to best manage it.

 

 

 

Topics include:

-What should a CMO be focused on?
-Functioning with restrictive capital
-Supporting a CEO who does not have experience in the therapeutic area you are in charge of
-The great balancing act
-The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Navigating the Complexities of Global Clinical Trials

Drs. Christopher Gallen, CEO at SK BioPharmaceuticals and Mitchell Katz, Executive Director, Medical Research Operations at Purdue Pharma, in a candid conversation on navigating the complexities of Global Clinical Trials and addressing topics including:

-Why global trials?
-Why are global trials so expensive?
-How are companies re-thinking global trials?
-What’s happening with global outsourcing?
-Thoughts on emerging markets and patient recruitment
-What can we do to help mitigate the risks of global trials?

The opinions shared by our guests are those of the speakers and do not necessarily reflect the opinions of their employers.

 


Clinical Air Episode #1 Clinical Trial Calling

Join Clinical Air host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer with guests Joe Kim, Clinical Operations Director, Shire and Dr Hugo Stevenson, physician and serial entrepreneur discuss innovation transforming the clinical trial space to include:

-Mobile technology and apps
-Clinical trials and diversity
-Google Glass for health
-Investigator database sharing
-Key motivations for innovators and more

The opinions shared by Craig and our guests are those of the speakers and do not necessarily reflect the opinions of their employers.